RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report
Personalized medicine using molecular-targeted drugs to achieve better therapeutic response and long-term prognosis is common practice for lung cancer treatment. However, in cases before gene batch tests were available, medical treatment continued without the detection of rare mutations. We report a...
Main Authors: | Kei Morikawa, Hiroshi Handa, Junko Ueno, Hajime Tsuruoka, Takeo Inoue, Naoki Shimada, Junki Koike, Seiji Nakamura, Yoshiharu Sato, Masamichi Mineshita |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1019932/full |
Similar Items
-
<i>RET</i>-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity
by: Antoine Desilets, et al.
Published: (2023-08-01) -
Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives
by: Sara Fancelli, et al.
Published: (2021-03-01) -
RET Inhibitors in Non-Small-Cell Lung Cancer
by: Priscilla Cascetta, et al.
Published: (2021-09-01) -
Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC
by: Elisa De Carlo, et al.
Published: (2024-02-01) -
Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma
by: Marine Sitbon, et al.
Published: (2023-01-01)